FOR IMMEDIATE RELEASE

Media Contacts:

press@minutia.co

Minutia receives $1,740,000 grant from National Institutes of Health

Berkeley, CA September, 2023 – Minutia, Inc., an innovative Oakland and Berkeley-based life sciences startup, announced today the award of a $1,740,000 grant from the National Institutes of Health (NIH), administered through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to help advance Minutia’s mission to create a functional cure for Type 1 diabetes.

This grant will support testing of Minutia’s lead inflammation-sensitive biosensor in stem cell-derived insulin producing organoids, designed to provide unique spectral readouts that result from a specific inflammatory response triggered in the cells. This de-risking of Minutia’s final cell therapy product will become a critical part of a functional cure for patients living with type 1 diabetes.

Housed in the Bakar BioEnginuity Hub at the University of California, the company began operations in January 2021, and has already demonstrated the efficacy of their robust insulin-producing cells and their intracellular sensors in animal models. In addition, Minutia has a proof of concept of their less-invasive transplant protocol in a PI-led phase 1/2 clinical trial.

Together with previous grants from the NIH and the JDRF, CIRM’s award positions Minutia as a key player in the development of Type 1 diabetes therapeutics and potential cures.

###

Minutia is a preclinical biotechnology company developing a unique approach to transplants of insulin-producing cells designed to lead to a cure for diabetes. Based in Oakland and Berkeley, CA, Minutia was launched in 2021 as a commercial spinout to research conducted at Duke University and UCSF.